MENURogel Cancer Center Members Attend 2024 ASCO Annual Meeting
Media contact: Eric Olsen, 734-764-2220 | Patients may contact Cancer AnswerLine™ 800-865-1125
Rogel Cancer Center faculty and trainees will attend, present and hold poster sessions at the American Society of Clinical Oncology meeting.
Check out the list of U-M presenters to support your colleagues. Connect with researchers on X/Twitter using #AACR24. Be sure to tag @UMRogelCancer.
Presenter information is sometimes incomplete. If your session is missing, please email the abstract link to [email protected].
*All times are in CDT*
May 31
Breast Cancer—Local/Regional/Adjuvant; Norah Henry, chair/moderator
2:45 PM – 4:15 PM
E451 | On Demand
June 1
PRESENTATIONS
Industry Expert Theater: Innovative Therapy Options and Research to Meet Diverse Patient Needs Across NSCLC; Christopher Lao, presenter
9:30 AM – 10:30 AM
Hall A | On Demand
POSTER SESSIONS: 1:30-4:30 PM
DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study. Sreenivasa R Chandana, presenter
Poster Bd #: 512b
Hall A | On Demand
A novel, noninvasive, multimodal screening test for the early detection of precancerous lesions and colorectal cancers using an artificial intelligence–based algorithm. D. Kim Turgeon, presenter
Poster Bd #: 290
Hall A | On Demand
Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04). Vaibhav Sahai, presenter
Poster Bd #: 96
Hall A | On Demand
June 2
PRESENTATIONS
Professional Coach: Building the Foundation; Jennifer J. Griggs, presenter
7:30 AM – 9:30 AM
S103 | On Demand
The Place of E-Cigarettes in Smoking Cessation Treatment and Policy: Approaches From Around the World; Kenneth E. Warner, presenter
8:00 AM – 9:15 AM
S402 | On Demand
Shake It Off: Can Less Be More?; Shitanshu Uppal, presenter
9:48-10:00 AM
Hall D2 | Live Stream
POSTER SESSIONS: 9-12 PM
Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial. Charles B Nguyen, presenter
Poster Bd #: 304b
Hall A | On Demand
Predictors of long-term prostate cancer mortality in men continuing prostate-specific antigen screening after age 70. Dana H. Chung, presenter
Poster Bd #: 346
Hall A | On Demand
Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC). Charles B Nguyen, presenter
Poster Bd #: 491
Hall A | On Demand
Clinical outcomes in salivary adenoid cystic carcinoma. Prarthana Dalal, presenter
Poster Bd #: 418
Hall A I On Demand
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial. Paul Swiecicki, presenter
Poster Bd #: 430b
Hall A I On Demand
Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy. Francis P. Worden, presenter
Poster Bd #: 414
Hall A I On Demand
June 3
PRESENTATIONS
An Update on the Fatigue SIO/ASCO Guidelines; Suzanna M. Zick, presenter
8:00-8:15 AM
S102 | On Demand
Navigating Therapeutic Dilemmas in Advanced Hepatocellular Carcinoma: Cases and Considerations; Baljendra Kapoor, presenter
11:30 AM – 12:30 PM
E451 | On Demand
Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.; Ulka N. Vaishampayan, presenter
1:50-2:02 PM
Hall D2 | Live Stream
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.; Erin Frances Cobain, presenter
5:00-5:12 PM
Hall B1 | Live Stream
POSTER SESSIONS: 9-12 PM
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Yasmin Karimi, presenter
Poster Bd #: 15
Hall A | On Demand
Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Yasmin Karimi, presenter
Poster Bd #: 22
Hall A | On Demand
Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study. Henry Dumke, presenter
Poster Bd #: 64
Hall A | On Demand
POSTER SESSIONS: 1:30-4:30 PM
Attitudes and engagement about cascade genetic testing in a population-based cohort of women diagnosed with cancer. Steven Jay Katz, presenter
Poster Bd #: 116
Hall A | On Demand
Association of social determinants of health (SDH), allostatic load (AL) and incident cancers in the multi-ethnic study of atherosclerosis (MESA). Ruth C. Carlos, presenter
Poster Bd #: 89
Hall A | On Demand
Impact of chemotherapy-induced peripheral neuropathy permanence on patients' preference to discontinue chemotherapy. Daniel Louis Hertz, presenter
Poster Bd #: 175
Hall A | On Demand